World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump
Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump’s U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS). The first implant was done by Duc Thinh Pham, MD, and Jane Wilcox, MD, at Northwestern Medicine Bluhm Cardiovascular Institute.
Impella BTR, a forward flow heart pump that is implanted via the axillary artery and sits in the left ventricle, can pump greater than six liters of blood per minute. It is smaller and less invasive than current LVADs and allows patients with chronic heart failure to have a longer-term minimally invasive heart pump option. Impella BTR’s design is intended to allow for heart recovery or heart remodeling with adjunctive therapies for patients with class III / IV heart failure. The vision of the Impella BTR development program is to provide a patient with home discharge and more than one year of full hemodynamic support.
“Bluhm Cardiovascular Institute at Northwestern Medicine is pleased to be the first in the world to implant Impella BTR as part of this important study,” said Dr. Wilcox, who is chief of heart failure treatment and recovery at Northwestern Medicine. “This novel technology could change the way we care for chronic heart failure patients by providing less invasive longer-term hemodynamic support with the goal of ultimately improving heart function in very sick patients.”
The intent of this study is to evaluate the safety of Impella BTR in patients who require left ventricular hemodynamic support, as well as the feasibility of supporting patients to recovery or their next therapy. The initial study will enroll 10 patients at five hospitals who will receive Impella BTR support for up to 28 days within a hospital setting. Patients will be securely monitored in the cloud via Impella Connect, giving providers access to Impella BTR status data 24/7. Once the study participant no longer requires hemodynamic support, the technology will be weaned and removed. Participants will be followed for 90 days.
“The first implant of Impella BTR is an important step toward our goal of improving patient care by providing a longer-term minimally invasive forward flow smart heart pump option with home discharge for patients with chronic heart failure,” said Michael Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “Overall, Abiomed is creating the innovation for the field of heart recovery and solving a healthcare crisis for this patient population with advanced research and technology.”
More detailed information about the study design can be found online at: https://clinicaltrials.gov/ct2/show/NCT05291884
Impella BTR is an investigational device, limited by federal law to investigational use only.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® are US FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are US FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella BTR™ is an investigational device, limited by federal law to investigational use only.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com/.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005391/en/
Contact information
Media:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com
Investors:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi and Ant International Pilot AI-Enabled Forecasting Solution to Enhance FX Risk Management for Airline Customers18.7.2025 05:30:00 EEST | Press release
Citi and Ant International announced today that they are piloting the use of Ant International's Falcon Time-Series Transformer (TST) Model to deliver an enhanced FX risk management solution for their customers. Developed with aviation clients as an initial use case, the solution aims to offer greater payment solutions for the airline industry, which processes billions of payment transactions annually. With airline travel set to continue growing, the joint solution combines Ant International's experience with airline payments and Citi's robust FX solutions to help the bank's clients manage their FX costs more efficiently. Ant International’s Falcon TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts future data points by learning complex patterns from large historical data sets using AI technology, the model helps businesses improve the efficiency and accura
AGC Launches Innovative Fluoroelastomer Without the Use of Surfactants or Fluorinated Polymerization Solvents18.7.2025 05:00:00 EEST | Press release
AGC (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai)(TOKYO:5201), a world-leading manufacturer of glass, chemicals and other high-tech materials, proudly announces the launch of surfactant and fluorinated polymerization solvent free grades in its fluoroelastomer “AFLAS™ FFKM” series; the SF grades (the “Products”). The newly developed Products are manufactured entirely without the use of any surfactants*1 or fluorinated polymerization solvents*2. The Products offer high performance equivalent to that of conventional products, while meeting the growing market demand for fluoroelastomers that do not use surfactants or fluorinated polymerization solvents during the manufacturing process. This has been achieved through AGC’s innovative, proprietary polymer manufacturing technology (Surfactant-Free & Fluoro Solvent-Free Technology, hereafter the “Technology”). Initially, this Technology will be applied to the high-temperature-resistant type of FFKM fluoroelastomers and new grades
Dubai Launches World’s First Icon Classification for Human–Machine Collaboration in Research and Publications17.7.2025 19:40:00 EEST | Press release
Dubai has launched the world’s first icon-based classification system to represent the level of human–machine collaboration in the process of producing research, publications, and public-facing content. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717193317/en/ Dubai launches world’s first icon classification for Human–Machine Collaboration in research and publications (Infographic: AETOSWire) Developed by the Dubai Future Foundation (DFF), the Human–Machine Collaboration (HMC) Icons offer a new global standard for transparency, clearly indicating the extent to which humans and AI worked together throughout the creation process. The classification is free to use, copyrighted for consistency, and openly available for researchers, publishers, and content creators worldwide. His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence, and Chairman of the
Battery Ventures Promotes Justin Rosner to Partner17.7.2025 16:47:00 EEST | Press release
Battery Ventures, a global, technology-focused investment firm, today announced nearly a dozen new internal promotions across four offices, including the elevation of Justin Rosner—a specialist in industrial technology and life-science tools—to partner. Battery also named four new principals across its venture-capital and private-equity practices, highlighting the firm’s penchant for promoting talent from within the firm. The new principals are Sudheendra Chilappagari in San Francisco; Michael Hoeksema in New York; Lior Mallul in Tel Aviv; and Lauren Wedell in Boston. Wedell and Mallul both joined Battery in 2018, while Hoeksema joined in 2017. Chilappagari, a former founder and technology product executive, joined the firm in 2021. “These promotions highlight Battery’s continued, global investment focus, even in the face of macroeconomic uncertainty, and our commitment to backing the most innovative companies across the private-equity and venture-capital markets,” said Jesse Feldman,
Andersen Consulting Adds Market Access Expertise with Prime Action in Brazil17.7.2025 16:30:00 EEST | Press release
Andersen Consulting strengthens its capabilities in Latin America with the addition of collaborating firm Prime Action Consulting, a firm specializing in market access strategy and channel management within the automotive, agribusiness, banking, pharmaceutical, and telecommunications sectors. Prime Action delivers end-to-end commercial consulting services to help organizations optimize their go-to-market strategies and improve performance across sales and distribution channels. The firm’s offerings include market access strategy, intelligent channel management, commercial and distribution policy design, channel development services, and training, all tailored to drive efficiency and customer alignment through structured processes, standards, and targeted execution. Working with top-tier companies across Latin America, Prime Action not only works in lockstep with clients from planning through implementation, but also post-implementation to provide appropriate training and evaluation to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom